Patterns of SPARC expression and basement membrane intactness at the tumour-brain border of invasive meningiomas

Neuropathology and Applied Neurobiology

Volumn 32, Issue 5, 2006, Pages 525-531

  Schittenhelm, J ^a   Mittelbronn, M ^a   Roser, F ^a   Tatagiba, M ^a   Mawrin, C ^b   Bornemann, A ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Brain invasion; Extracellular matrix; Meningioma; Osteonectin; Plial glial membrane; SPARC

Indexed keywords

COLLAGEN TYPE 4; EPITHELIAL MEMBRANE ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; OSTEONECTIN;

ADULT; AGED; ARTICLE; BASEMENT MEMBRANE; BRAIN TUMOR; CANCER GRADING; CANCER INVASION; DISEASE COURSE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MENINGIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINDLE CELL; WORLD HEALTH ORGANIZATION;

EID: 33748743878     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2006.00761.x     Document Type: Article

References (21)

1. Murphy-Ullrich JE. The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? J Clin Invest 2001; 107: 785-90
2. Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 2001; 107: 1049-54
3. Framson PE, Sage EH. SPARC and tumour growth: where the seed meets the soil? J Cell Biochem 2004; 92: 679-90
4. Porte H, Triboulet JP, Kotelevets L, Carrat F, Prévot S, Nordlinger B, DiGioia Y, Wurtz A, Comoglio P, Gespach C, Chastre E. Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human oesophageal carcinoma: implications for prognosis. Clin Cancer Res 1998; 4: 1375-82
5. Wang CS, Lin KH, Chen SL, Chan YF, Hsueh S. Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. Br J Cancer 2004; 91: 1924-30
6. Bellahcéne A, Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 1995; 146: 95-100
7. Parker BS, Argani P, Cook BP, Liangfeng H, Chartrand SD, Zhang M, Saha S, Bardelli A, Jiang Y, St. Martin TB, Nacht M, Teicher BA, Klinger KW, Sukumar S, Madden SL. Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res 2004; 64: 7857-66
8. Briggs J, Chamboredon S, Castellazzi M, KerryJA, Bos TJ. Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene 2002; 21: 7077-91
9. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, Podhajcer OL. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med 1997; 3: 171-6
10. Tai IT, Dai M, Owen DA, Chen LB. Genome-wide expression analysis of therapy-resistant tumours reveals SPARC as a novel target for cancer therapy. J Clin Invest 2005; 115: 1492-502
11. Yiu GK, Yee-Chan W, Ng SW, Chan PS, Cheung KK, Berkowitz RS, Mok SC. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 2001; 159: 609-22
12. Abeysinghe HR, Cao Q, Xu J, Pollock S, Veyberman Y, Guckert NL, Keng P, Wang N. Thy1 expression is associated with tumour suppression of human ovarian cancer. Cancer Genet Cytogenet 2003; 143: 125-32
13. Schultz C, Lemke N, Ge S, Golembieski WA, Rempel SA. Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumour growth in vivo. Cancer Res 2002; 62: 6270-7
14. Dhanesuan N, Sharp JA, Blick T, Price JT, Thompson EW. Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition. Breast Cancer Res Treat 2002; 75: 73-85
15. Koblinski JE, Kaplan-Singer BR, Vanosdol SJ, Wu M, Engbring JA, Wang S, Goldsmith CM, Piper JT, Vostal JG, Harms JF, Welch DR, Kleinman HK. Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Res 2005; 65: 7370-7
16. Brekken RA, Puolakkainen P, Graves DC, Workman G, Lubkin SR, Sage EH. Enhanced growth of tumours in SPARC null mice is associated with changes in the ECM. J Clin Invest 2003; 111: 487-95
17. Fathallah-Shaykh HM, He B, Zhao LJ, Engelhard HH, Cerullo L, Lichtor T, Byrne R, Munoz L, von Roenn K, Rosseau GL, Glick R, Sherman C, Farooq K. Genomic expression discovery predicts pathways and opposing functions behind phenotypes. J Biol Chem 2003; 278: 23830-3
18. Rempel SA, Ge S, Gutierrez JA. SPARC: a potential diagnostic marker of invasive meningiomas. Clin Cancer Res 1999; 5: 237-41
19. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK. The WHO classification of tumours of the nervous system. J Neuropathol Exp Neurol 2002; 61: 215-25
20. Perry A, Gutmann DH, Reifenberger G. Molecular pathogenesis of meningiomas. J Neurooncol 2004; 70: 183-2202
21. Fritz J, Roser F, Tatagiba M, Bornemann A. The basement membrane at the tumour-brain interface of brain-invasive grade I meningiomas. Neuropathol Appl Neurobiol 2005; 31: 339-42